Please Note: This trial is no longer enrolling new participants
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1).
Protocol No. | CTO-RYZ101-201 | Scope | National |
---|---|---|---|
Principal Investigator | Kathy Miller | Treatment Type | Treatment |
Age Group | Adult | Phase | Phase I/II |